Tessellate BIO announces appointment of Lara Boyd as Chief Business Officer

Amsterdam, the Netherlands and Stevenage, UK – 4 November 2024 - Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment of Dr. Lara Boyd as Chief Business Officer.

Lara joins Tessellate BIO from F-star Therapeutics, an innovation focused biotech company dedicated to delivering next-generation multispecific antibody therapeutics, where she held a number of senior roles, most recently VP Head of BD and Corporate Strategy, responsible for end-to-end business development activities. Prior to joining F-star Lara held  business development roles at Cancer Research Technology and Cancer Research UK. Lara completed her PhD at the MRC Genome Damage and Stability Centre and then undertook post-doctoral research at the Barts Cancer Institute.

Andree Blaukat, CEO, Tessellate BIO said:

Lara brings exceptionally strong and relevant experience to Tessellate BIO, with a proven track record in business development and background in cancer research. I have no doubt she will add considerable strength to our leadership team as we continue our rapid growth and development.

Lara Boyd said: “I am hugely excited to be joining Tessellate BIO. The development of new treatments for cancer has driven my career both in research and in business, and Tessellate BIO’s approach to precision medicine represents an enormous opportunity for patients whose needs are not being met by current medicines. I look forward to working with the team to deliver the Company’s vision of turning cancer patients into cancer survivors.”